Abstract
This article aims to give an overview on etiology, diagnosis and treatment options of osteonecrosis of the jaw bone among cancer patients receiving anti-resorptive drugs (ARDs). The physiologic bone function of continuous resorption and buildup is modified by the use of ARDs. Although ARDs proved to reduce pain and to improve the quality of life in patients with metastasizing bone disease, side effects such as medication related osteonecrosis of jaw bone (MRONJ) have been frequently reported since ARDs were firstly introduced. The new generation of ARDs such as Denosumab is associated with the same incidence of MRONJ among cancer patients. The etiology of MRONJ is not entirely understood and many hypotheses have been proposed. ARDs can modify the hard tissues directly by accumulation in the bone, or indirectly by suppression of the osteoclasts, inhibition of angiogenesis and vascularity. Some ARDs such as Bisphosphonates have reportedly the capacity to interfere directly and indirectly with the bone physiology. MRONJ can be a debilitating disease with non healing freely exposed bone in the oral cavity in patients, who already suffer from a primary cancerous disease. Knowledge of MRONJ as a potential side effect of ARDs is crucial for health professionals treating patients with bone modulating drugs.
Keywords: Anti-resorptive drugs, bisphosphonates, denosumab, jaw necrosis, osteoporosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Anti-resorptive Drugs and their Impact on Maxillofacial Bone among Cancer Patients
Volume: 15 Issue: 6
Author(s): Farzad Borumandi, Tara Aghaloo, Luke Cascarini, Alexander Gaggl and Kunmi Fasanmade
Affiliation:
Keywords: Anti-resorptive drugs, bisphosphonates, denosumab, jaw necrosis, osteoporosis.
Abstract: This article aims to give an overview on etiology, diagnosis and treatment options of osteonecrosis of the jaw bone among cancer patients receiving anti-resorptive drugs (ARDs). The physiologic bone function of continuous resorption and buildup is modified by the use of ARDs. Although ARDs proved to reduce pain and to improve the quality of life in patients with metastasizing bone disease, side effects such as medication related osteonecrosis of jaw bone (MRONJ) have been frequently reported since ARDs were firstly introduced. The new generation of ARDs such as Denosumab is associated with the same incidence of MRONJ among cancer patients. The etiology of MRONJ is not entirely understood and many hypotheses have been proposed. ARDs can modify the hard tissues directly by accumulation in the bone, or indirectly by suppression of the osteoclasts, inhibition of angiogenesis and vascularity. Some ARDs such as Bisphosphonates have reportedly the capacity to interfere directly and indirectly with the bone physiology. MRONJ can be a debilitating disease with non healing freely exposed bone in the oral cavity in patients, who already suffer from a primary cancerous disease. Knowledge of MRONJ as a potential side effect of ARDs is crucial for health professionals treating patients with bone modulating drugs.
Export Options
About this article
Cite this article as:
Borumandi Farzad, Aghaloo Tara, Cascarini Luke, Gaggl Alexander and Fasanmade Kunmi, Anti-resorptive Drugs and their Impact on Maxillofacial Bone among Cancer Patients, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (6) . https://dx.doi.org/10.2174/1871520615666150325232857
DOI https://dx.doi.org/10.2174/1871520615666150325232857 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteomic Analysis of the Kidney in Rat Biliary Cirrhosis
Current Proteomics Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology Anti-Angiogenic Agents in Pancreatic Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets Targeted Therapies in Lung Cancer
Current Pharmaceutical Design Diagnostic and Prognostic Markers in Differentiated Thyroid Cancer
Current Genomics G-quadruplex DNA Aptamers and their Ligands: Structure, Function and Application
Current Pharmaceutical Design Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Von Hippel-Lindau Disease
Current Molecular Medicine Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Is Tretinoin Still a Key Agent for Photoaging Management?
Mini-Reviews in Medicinal Chemistry Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders